Mycobacterium gordonae, a nontuberculous acid-fast bacterium (AFB) of low pathogenicity. The specimens were submitted from 34 patients who came from various inpatient and outpatient services. Four patients were begun on antimycobacterial therapy on the basis of an AFB isolate which was later identified as M. gordonae. Isolation of M. gordonae was associated with use of the BACTEC TB system (BACTEC TB; Becton Dickinson Diagnostic Instrument Systems, Towson, Md.) and an antimicrobial solution, BACTEC PANTA PLUS (PANTA; Becton Dickinson Diagnostic Instrument Systems). The manufacturer reported that two lots (B9K1 and C9K1) of PANTA kits containing a single production lot (N8C1) of PANTA, which had been shipped to 173 laboratories, had been contaminated with M. gordonae. A survey of mycobacteriology laboratories in the United States revealed that, during April to July 1989, the M. gordonae isolation rate was 5.8/1,000 AFB specimens processed at laboratories that did not use BACTEC TB, 11.4/1,000 AFB specimens at laboratories that used BACTEC TB but not the implicated lot of PANTA, and 23.5/1,000 AFB specimens at laboratories that used BACTEC TB and the lot of implicated PANTA. Intrinsic contamination of PANTA was attributed to ineffective sterilization of water used in the manufacturing process and was not detected prior to product shipment because cultures for AFB were not part of the quality control regimen. This episode emphasizes that clinical laboratories can detect pseudoepidemics promptly if they are alert to abrupt increases in isolation rates, especially of unusual or generally nonpathogenic organisms.
Mycobacterium gordonae, a nontuberculous mycobacterium, is commonly found in water and sputum (22) . In a survey of state health departments, it was the third most commonly isolated acid-fast bacterium (AFB), comprising 14.6% of all isolates (7) . Despite this ubiquity, M. gordonae rarely causes disease, and the vast majority of isolates represent harmless commensal or contaminant organisms introduced during specimen collection or processing (22) . M. gordonae isolates occurring in the absence of invasive disease may create diagnostic confusion and may prompt unnecessary antimycobacterial therapy, especially in the period between detection of AFB growth in laboratory cultures and identification of the growth as M. gordonae.
The BACTEC TB system (BACTEC TB; Becton Dickinson Diagnostic Instrument Systems, Towson, Md.) is a radiometric method for detection of mycobacterial growth in vials of medium containing 14C-labeled substrate (BACTEC 12B medium). A solution of five antimicrobial agents (polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin), BACTEC PANTA PLUS (PANTA; Becton Dickinson Diagnostic Instruments), is used to suppress growth of non-AFB microorganisms (19) . BACTEC TB allows detection of AFB more rapidly than conventional solid AFB medium does (17) . We present here the results of our investigation of BACTEC TB cultures contaminated with M. gordonae. To our knowledge, this is the first published report of an episode of AFB pseudoinfection caused by a commercially distributed product. * (Fig. 1 ). There was a highly significant increase in the M. gordonae isolation rate during the "epidemic" period (4 May 1989 to 1 July 1989) compared with that during the base-line period (1 November 1985 to 1 May 1989; Table 1 ). When isolation rates by medium type were compared during these periods, the numbers of M. gordonae isolated only from BACTEC TB increased significantly from 16/12,056 to 46/603 (P < 0.001), whereas rates of isolation from other media or simultaneously from BACTEC TB and other media showed nonsignificant changes (Table  1 ). These data confirm that an outbreak of M. gordonae isolates occurred and was associated with the use of the BACTEC TB system.
The 46 specimens that met the case definition came from a variety of sites: 26 (56.5%) from sputum; 7 (15.2%) from urine; 4 (8.7%) from cerebrospinal fluid (CSF); 4 (8.7%) from tissue or wound; and 1 (2.2%) each from blood, bronchial brushing, bronchial washing, nasal swab, and a gastric aspirate. The case-specimens were submitted from several inpatient services and outpatient areas.
Smears of all case-specimens were initially negative for AFB. AFB were isolated a median of 21 days after specimen submission and were identified as nontuberculous mycobac- of PANTA from this lot performed by the manufacturer were reported to be positive for M. gordonae. Cultures were positive regardless of whether the dry PANTA was dissolved in sterile water or in the diluent supplied in PANTA kits, indicating contamination of the antibiotic powder itself. Cultures of several other lots of PANTA and cultures of BACTEC TB media were reported to be negative. According to the manufacturer, recall letters dated 8 August 1989 were sent to 173 laboratories that had received this lot of PANTA. The manufacturer's review did not reveal a definite mechanism of contamination, but suggested that the deionized water used in preparing one batch of PANTA had not been effectively autoclaved. PANTA is not terminally sterilized after production because of fears that heat would inactivate the antimicrobial agents and that filtration would reduce the concentration of amphotericin B. Before the episode of contamination, quality control cultures for aerobic and anaerobic bacteria, but not AFB, were performed. Subsequently, cultures for AFB were added.
Results of survey of mycobacteriology laboratories. The survey of mycobacteriology laboratories was returned by 321 (53%) laboratories. Laboratories were excluded from analysis if they did not process AFB specimens (n = 7), did not provide numbers of total specimens processed and numbers of M. gordonae isolated (n = 38), could not be classified as either using or not using BACTEC TB on a routine basis (n = 5), or were not located in the United States (n = 2). After these exclusions, data from 269 laboratories were analyzed.
The pooled M. gordonae isolation rate was lowest for laboratories that did not use BACTEC TB (5.8/1,000), somewhat higher for those that used BACTEC TB but that did not receive PANTA lot N8C1 (11.4/1,000), and highest for those that used BACTEC TB and that received PANTA lot N8C1 (23.5/1,000; Table 2 ). The median duration of specimen decontamination was 15 min for all three groups and mean numbers of AFB media used were similar, but laboratories that used BACTEC TB tended to process more specimens than laboratories that did not use BACTEC TB (Table 2) .
M. gordonae isolation rates at individual laboratories are shown in Fig. 2 . The 32 laboratories that used BACTEC TB and that received PANTA lot N8C1 had the highest isolation rates. Within this group, however, there was considerable variation: 15 (47%) laboratories had rates below 10/1,000, and 11 (34%) laboratories had rates above 30/1,000.
Because of differences between BACTEC TB users and nonusers in the numbers of specimens processed, we calculated Mantel-Haenszel relative risks, stratifying laboratories by numbers of specimens processed per 4 months (<200 specimens [n = 91], 200 to 500 specimens [n = 89], and >500 specimens [n = 89]). Compared with laboratories that did not use BACTEC TB, laboratories that used BACTEC TB and that received PANTA lot N8C1 were significantly more likely to have had an M. gordonae isolation rate of .20/1,000 (relative risk = 5.5; 95% confidence interval = 2.6, 11.6; P < 0.001). There was no significant difference between BAC-TEC TB users that did not receive PANTA lot N8C1 and BACTEC TB nonusers (relative risk = 2.4, 95% confidence interval = 0.9, 6.7; P = 0.16).
DISCUSSION
There are a number of published case reports of invasive disease caused by M. gordonae. Because of the frequency of contamination of cultures with this common environmental organism, cases in which M. gordonae has been isolated only once may represent contamination rather than true infection (2, 9, 13, 18). In the absence of clinical evidence of infection, colonization of the respiratory tract may explain some sputum isolates (11) . Reported cases in which M. gordonae was isolated at least twice, and in some cases multiple times, include three pulmonary infections (4, 10, 12) , a peritoneal infection in a patient receiving continuous ambulatory peritoneal dialysis (15) , meningitis in a hydrocephalic child with a ventriculoatrial shunt (6) , endocarditis of a prosthetic valve (14) , cutaneous infections of the foot and wrist (16) , and a patient with the acquired immune deficiency syndrome with M. gordonae isolated from both sputum and bone marrow (3). These case reports indicate that, since M. gordonae occasionally causes disease, isolates cannot always be attributed to contamination or colonization. As expected of an organism of low pathogenicity, no outbreak or cluster of true M. gordonae infections has been reported. M. gordonae has, however, been implicated in a number of pseudoepidemics. Nonsterile deionized water in a pathology laboratory was the apparent cause of a cluster of spurious M. gordonae isolates (21) . M. gordonae isolation from sputum specimens has been attributed to rinsing of patients' mouths with tap water prior to sputum induction with aerosol (5). M. gordonae was isolated from bronchoscopy specimens of 52 individuals at Y-NHH from January 1975 through June 1977. The contamination was attributed to green dye added to topical anesthetic by one physician. The low pathogenic potential of M. gordonae was illustrated by the absence of clinical infections attributed to this organism, despite inoculation of an estimated 500,000 organisms into each patient's respiratory tract (20) . To our knowledge, there have been no previous published reports of pseudoinfection with M. gordonae (or any other AFB) caused by contamination of a commercially distributed product.
Problems which may be caused by episodes of pseudoinfection include delay of appropriate therapy, overgrowth of cultures with contaminants, and risks and costs associated with further diagnostic procedures and unnecessary therapy (8) . The clinical laboratory must expend time and resources to identify the spurious isolates, determine their source, and notify physicians of the problem. Pseudoinfection with mycobacteria may be particularly troublesome because of the long periods needed for growth and identification of isolates.
Our investigation at Y-NHH pointed to pseudoinfection since case-specimens came from a variety of sites and services and isolation of M. gordonae was associated with use of BACTEC TB and PANTA. A median period of 37 days elapsed between detection of mycobacterial growth and identification of the growth as M. gordonae. During this period, four patients were started on antimycobacterial therapy. The potential for adverse effects from unnecessary antimycobacterial therapy (1) clearly existed. The number of patients receiving such unnecessary therapy was probably limited by early recognition of the problem by laboratory personnel.
The results of our survey of mycobacteriology laboratories must be interpreted with caution because of the relatively low response rate (53%), the small number of responding laboratories that received the implicated PANTA (n = 32), and the possibility that laboratories with higher M. gordonae isolation rates may have been more likely to return the questionnaire. Nevertheless, the survey provides evidence that, during the period that lot N8C1 was reported to have been in use, laboratories that received PANTA lot N8C1 had higher M. gordonae isolation rates than did laboratories that did not use BACTEC TB. Laboratories that used BACTEC TB but not the implicated PANTA also had higher isolation rates than did BACTEC TB nonusers, although the difference was not statistically significant. The higher rate among BACTEC TB users that did not receive the implicated PANTA may have been due to greater recovery of naturally occurring M. gordonae by BACTEC TB.
The survey also revealed that only some of the laboratories that used BACTEC TB and that received PANTA lot N8C1 were significantly affected by this episode of contamination. Such selective involvement may have been caused by differences in laboratory procedures not covered by our survey or may indicate that not all vials of PANTA lot N8C1 were contaminated. Also, the dates covered by our questionnaire (1 Appropriate quality control should prevent the distribution of contaminated products. Before this episode, the manufacturer's quality control procedures for PANTA did not include culturing for AFB; following this episode, the manufacturer has reported that culturing for AFB has been added. This episode highlights the fact that clinical laboratories must critically evaluate increases in isolation rates, especially when unusual or generally nonpathogenic organisms are involved, so that pseudoepidemics can be detected promptly.
